CYP1A2 and neoplasm: E2 treatment led to the reduction in the mass of both cases “E2 groups, Fig 4A”, however E2-mediated reduction of CYP1A2-oeverexpressing tumor was more robust than that of the tumor without CYP1A2 overexpression “Fig 4B, 45% vs 22%, p<0.05”.